CF
51
-5
KMB
44
11
XRX
56
-3
MRK
35
-3
CVS
58
-2
EXPE
72
-9
AIG
60
3
SE
80
-8
EOG
45
3
NVDA
61
-2
LEG
55
2
ILMN
45
-4
SEE
61
-2
HAS
68
3
CCI
26
3
ZBH
50
3
CAH
69
2
BXP
41
3
M
36
-3
CCL
68
-2
CF
51
-5
KMB
44
11
XRX
56
-3
MRK
35
-3
CVS
58
-2
EXPE
72
-9
AIG
60
3
SE
80
-8
EOG
45
3
NVDA
61
-2
LEG
55
2
ILMN
45
-4
SEE
61
-2
HAS
68
3
CCI
26
3
ZBH
50
3
CAH
69
2
BXP
41
3
M
36
-3
CCL
68
-2
Financhill
Back

Range Cancer Therapeutics ETF Stock Predictions

Missed investing in Uber? Don't Miss Mode.

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
23

CNCR
Range Cancer Therapeutics ETF

Last Price:
$8.86
Seasonality Move:
2.51%

7 Day Trial

ALL ACCESS PASS

$ 7

The key to a $1.3T opportunity

This is a paid advertisement for Pacaso's Regulation A offering. Please read the offering circular and related risks at invest.pacaso.com.

Range Cancer Therapeutics ETF Stock Forecast

  • Over the next 52 weeks, Range Cancer Therapeutics ETF has on average historically fallen by 4.7% based on the past 9 years of stock performance.
  • Range Cancer Therapeutics ETF has fallen lower in 4 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 44.44%
  • Is Range Cancer Therapeutics ETF Stock Undervalued?
    The current Range Cancer Therapeutics ETF [CNCR] share price is $8.86. The Score for CNCR is 23, which is 54% below its historic median score of 50, and infers higher risk than normal.
  • CNCR is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.

Will Range Cancer Therapeutics ETF Stock Go Up Next Year?

  • Over the next 52 weeks, Range Cancer Therapeutics ETF has on average historically fallen by 4.7% based on the past 9 years of stock performance.

Range Cancer Therapeutics ETF Stock Rating

Sell
23
Range Cancer Therapeutics ETF (CNCR) is a Sell

Is Range Cancer Therapeutics ETF overpriced?

  • Range Cancer Therapeutics ETF has fallen lower in 4 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 44.44%

Range Cancer Therapeutics ETF Stock Price History

Is CNCR stock going to rise?

  • The current trend is moderately bearish and CNCR is experiencing selling pressure, which indicates risk of future bearish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Industry:
Sector:
Type:
etf
Website:

52-Week Data

52-Week High:
16.27
52-Week Low:
7.88

Prediction Charts

Market Cap:
0
Price in USD:
8.86
Volume:
1.2K
Beta:
1.15

Technical Analysis

SMA50:
9.87
SMA100:
11.12
SMA200:
12.92
52-Wk Change:
-41.86%

Stock Predictions

  • Is Range Cancer Therapeutics ETF stock public?
    Yes, Range Cancer Therapeutics ETF is a publicly traded company.
  • What is the Range Cancer Therapeutics ETF stock quote today?
    The Range Cancer Therapeutics ETF stock price is 8.86 USD today.
  • How to buy Range Cancer Therapeutics ETF stock online?
    You can buy Range Cancer Therapeutics ETF shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Apr-22 9.44 9.65 9.65 9.44
Apr-23 9.96 9.87 10.12 9.87
Apr-24 9.88 10.16 10.16 9.86
Apr-25 9.96 9.77 9.96 9.77
Apr-28 9.87 9.94 10.02 9.81
Apr-29 9.80 9.77 9.89 9.77
Apr-30 9.64 10.01 10.01 9.64
May-1 10.05 9.95 10.05 9.83
May-2 10.09 10.17 10.30 10.09
May-5 10.01 9.85 10.01 9.85
May-6 9.68 8.96 9.68 8.96
May-7 8.84 8.85 8.87 8.84
May-8 8.99 9.12 9.12 8.94
May-9 9.17 8.86 9.17 8.86

Range Cancer Therapeutics ETF Earnings

Data Unavailable

Range Cancer Therapeutics ETF Forecast Revenue Growth

Data Unavailable

* Range Cancer Therapeutics ETF stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.